Immutep's eftilagimod shows a 17.6-month survival benefit in head and neck cancer. Find out how and why IMMP is continuing to ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC).

Cancer completely disappeared from two-thirds of 24 patients treated with a combination of the antibody petosemtamab and ...

Despite a congressional mandate to expand care for veterans, internal Veterans Affairs messages obtained by ProPublica paint ...

DelveInsight’s Head and Neck Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

Adding pembrolizumab before and after surgery reduced recurrence and improved response in patients with locally advanced head ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

A reduced dose of elective radiation is safe and does not compromise treatment efficacy in patients with head and neck ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...